New Life Health is a US-based telehealth startup that combines psychedelic-assisted therapy and a health-tracking app. Previously, the app was only available as part of its internal service. However, the startup is now opening up its “new application” and its “Nue Score” are freely available to any patient receiving ketamine treatment, not just itself. The U.S. Food and Drug Administration has officially recognized A variant of ketamine, called “Esketamine,” is used as a drug to treat depression.
The Nue Life app allows patients receiving ketamine in the US to join Nue Life’s membership service to supplement their medication. The app features biometric data integration (Apple Healthkit and Google Fit) and access to “Nue Score” progress tracking. Home ketamine therapy combines music therapy with a data-led “quantified self” approach.
All users receiving ketamine therapy in the United States, including all treatment modalities via lozenge, intramuscular (IM) and intravenous (IV), will have access to the Nue Life app.
So, as Nue Life rolls out these new services, it’s likely to expand its market reach.
Last year Nue Life said it raised a $23 million Series A equity round led by Obvious Ventures (co-founded by Twitter co-founder Ev Williams) that was part venture debt, part equity. This is after the seed round in 2021.
The company has now also closed an additional $1.9 million in funding from existing investors to support a free app launch.
Nue Life says it now provides “at-home” ketamine therapy to more than 8,000 patients across the U.S., combined with a library, app and aftercare program.
Juan Pablo Cappello, co-founder and CEO of Nue Life, said in a statement: “We have seen 20-30% improvement over baseline in patients taking advantage of our complete program. We are now pleased to present All of these tools, content, and plans for preparation and aftercare are available to all users who may be receiving ketamine treatment from providers across the United States, whether at home or in a clinic or office.”
Nue Life also appointed Dr Frank Drummond as its new chief medical officer. Dr. Drummond was previously the National Chief Marketing Officer for HCA’s Behavioral Health Practice.
In March, TechCrunch caught up with Mindbloom CEO Dylan Beynon to find out how he sees the future of psychedelic mental health.